3 results match your criteria: "Groupe Hospitalier Region Mulhouse-Sud-Alsace (GHRMSA)[Affiliation]"
Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
J Neurol
October 2023
Centre NeuroVasculaire Translationnel, Centre de Référence CERVCO, Département de Neurologie, Hôpital Lariboisière, GHU AP-HP Nord, Université de Paris, Paris, France.
Article Synopsis
- The study examines the prevalence and predictors of cerebral lesions in patients with immune thrombotic thrombocytopenic purpura (iTTP) and hemolytic uremic syndrome (HUS) during their acute phases.
- One-third of the 73 patients analyzed showed acute ischemic lesions on MRI, and neurological symptoms were not significantly different between iTTP and HUS cases.
- Key factors predicting these lesions included the presence of old infarcts, elevated blood pulse pressure, and a diagnosis of iTTP, indicating potential areas for enhanced treatment approaches.*
Background: The prevalence, prognostic role, and diagnostic value of blood pressure in immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs) remain unclear.
Methods: Using a national cohort of iTTP ( = 368), Shigatoxin-induced hemolytic uremic syndrome ( = 86), atypical hemolytic uremic syndrome ( = 84), and hypertension-related thrombotic microangiopathy ( = 25), we sought to compare the cohort's blood pressure profile to assess its impact on prognosis and diagnostic performances.
Results: Patients with iTTP had lower blood pressure than patients with other TMAs, systolic (130 [interquartile range (IQR) 118-143] vs 161 [IQR 142-180] mmHg) and diastolic (76 [IQR 69-83] vs 92 [IQR 79-105] mmHg, both < 0.
Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome.
J Blood Med
February 2020
Laboratory of Immunology, Groupe Hospitalier Region Mulhouse-Sud-Alsace (GHRMSA), Mulhouse 68070, France.
Acquired von Willebrand syndrome (AVWS) in the setting of Waldenström macroglobulinemia (WM) is a challenging condition. No real standard of care is recommended for these patients, although the therapeutic strategy should include a rapid approach to the emergency bleeding events and to the underlying malignant lymphoid disorder. We report here our experience treating three elderly patients with these concomitant hematologic entities.
View Article and Find Full Text PDF